Viking begins VENTURE trial of dual glp-1/gip receptor agonist VK2735 for obesity
Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like...
top of page
Browse by category
Search
Viking initiates study to evaluate dual GLP-1/GIP receptor agonist VK2735
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...
Browse by tag
bottom of page